Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.
2.

Cutaneous T cell lymphoma: the helping hand of dendritic cells.

Edelson RL.

Ann N Y Acad Sci. 2001 Sep;941:1-11. Review.

PMID:
11594563
3.

Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas.

Cho DY, Lin SZ, Yang WK, Hsu DM, Lee HC, Lee WY, Liu SP.

Cell Transplant. 2009;18(9):977-83. doi: 10.3727/096368909X12483162196962. Epub 2009 May 13. Review.

PMID:
19523342
4.

Immunotherapy of multiple myeloma.

Ruffini PA, Kwak LW.

Semin Hematol. 2001 Jul;38(3):260-7. Review.

PMID:
11486314
5.

Alternative pathways of cell death to circumvent pleiotropic resistance in myeloma cells: role of cytotoxic T-lymphocytes.

Shtil AA, Turner JG, Dalton WS, Yu H.

Leuk Lymphoma. 2000 Jun;38(1-2):59-70. Review.

PMID:
10811448
6.

A comparison of the cytolytic properties of murine primary CD8+ cytotoxic T lymphocytes and cloned cytotoxic T cell lines.

Nagler-Anderson C, Allbritton NL, Verret CR, Eisen HN.

Immunol Rev. 1988 Mar;103:111-25. Review.

PMID:
3134291
7.

Presentation of tumor antigens.

Hart DN, Schultze JL, Stewart AK.

Semin Hematol. 1999 Jan;36(1 Suppl 3):21-5. Review.

PMID:
9989485
8.

[Role of CTL in liver injury of patients with HCV infection].

Hiroishi K, Matsumura T, Imawari M.

Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):159-63. Review. Japanese. No abstract available.

PMID:
15359785
9.

Immunotherapy using dendritic cells against multiple myeloma: how to improve?

Nguyen-Pham TN, Lee YK, Kim HJ, Lee JJ.

Clin Dev Immunol. 2012;2012:397648. doi: 10.1155/2012/397648. Epub 2012 Mar 15. Review.

10.

Human tumor antigens recognized by T lymphocytes: implications for cancer therapy.

Wang RF, Rosenberg SA.

J Leukoc Biol. 1996 Sep;60(3):296-309. Review.

PMID:
8830785
11.

Tumor cell lysates as immunogenic sources for cancer vaccine design.

González FE, Gleisner A, Falcón-Beas F, Osorio F, López MN, Salazar-Onfray F.

Hum Vaccin Immunother. 2014;10(11):3261-9. doi: 10.4161/21645515.2014.982996. Review.

12.

Immunoregulation of murine and human myeloma.

Hoover RG, Kornbluth J.

Hematol Oncol Clin North Am. 1992 Apr;6(2):407-24. Review.

PMID:
1582982
13.

Immunotherapy of cancer using dendritic cells.

Morse MA, Lyerly HK.

Cytokines Cell Mol Ther. 1998 Mar;4(1):35-44. Review.

PMID:
9557215
14.
15.

Novel immunotherapies.

Yi Q.

Cancer J. 2009 Nov-Dec;15(6):502-10. doi: 10.1097/PPO.0b013e3181c51f0d. Review.

16.

Dendritic cell-based vaccine: a promising approach for cancer immunotherapy.

Tarte K, Klein B.

Leukemia. 1999 May;13(5):653-63. Review.

PMID:
10374867
17.

Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma.

Hart DN, Hill GR.

Immunol Cell Biol. 1999 Oct;77(5):451-9. Review.

PMID:
10540212
18.

Idiotypic vaccination in B-cell malignancies.

Bianchi A, Massaia M.

Mol Med Today. 1997 Oct;3(10):435-41. Review.

PMID:
9358470
19.

Dendritic cell-dead cell interactions: implications and relevance for immunotherapy.

Fonteneau JF, Larsson M, Bhardwaj N.

J Immunother. 2001 Jul-Aug;24(4):294-304. Review.

PMID:
11565831
20.

Clonal cytotoxic T cells in myeloma.

Sze DM, Brown RD, Yuen E, Gibson J, Ho J, Raitakari M, Basten A, Joshua DE, Fazekas de St Groth B.

Leuk Lymphoma. 2003 Oct;44(10):1667-74. Review.

PMID:
14692517

Supplemental Content

Support Center